• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA mulls next move in compounding court decision

October 1, 2006

Washington - While compounding proponents claim victory to a recent district court decision, the Food and Drug Administration (FDA) is weighing its options.

WASHINGTON — While compounding proponents claim victory to a recent district court decision, the Food and Drug Administration (FDA) is weighing its options.

FDA spokesperson Susan Cruzan says the agency "will consider all options, including seeking an appeal."

The Aug. 30 decision in the United States District Court, Western District of Texas Midland-Odessa Division, issued a partial summary judgment in a cased filed in 2004 by 10 pharmacies against FDA.

As part of the ruling, Judge Robert Junell states compounding is a legal practice, adding compounding from bulk ingredients for non-food animals does not violate the Federal Food, Drug and Cosmetic (FD&C) Act, as asserted by FDA.

Advertisement

"Congress intended to declare that compounding is an approved and legal practice," Junell says.

The judge's comments were lauded by compounding advocates.

L.D. King, executive director of the International Academy of Compounding Pharmacists, reports, "FDA took a hard-line approach. The big issue is compounding is not illegal. The compounding of a medication pursuant to a valid prescription is not creating a new drug. That's the biggest point coming out of this decision."

The 26-page decision makes others.

"The court finds that the exemption for compounded drugs from the new drug definition is limited to compounds which are made in reasonable quantities upon receipt of a valid prescription for an individual patient from a licensed practitioner," the decision states.

It begs the question: What's reasonable?

Ron Phillips, vice president of legislative affairs for the Animal Health Institute, a group that represents animal health drug makers, says: "The main points are consistent with what we and AVMA have been saying; compounding is legal in reasonable quantities and in response to a prescription. It is easy to agree that manufacturing is not legal, but where is the line and how do you tell the difference?"

Other court findings include:

  • If compounding is a legal activity, a process approved by the Supreme Court (albeit in dicta), "then any drugs created through the compounding process must exempt from the new drug definitions found in the (FD&C) Act."

  • FDA also draws a line between compounding for an individual patient and compounding that rises to the level of manufacturing in its compliance policy guide. The court found "this distinction further supports the exemption of compounded drugs from the new drug definitions, if the drugs are created for an individual patient on the basis of a prescription from a licensed practitioner."

  • Pharmacies may compound drugs from legal bulk ingredients for non-food animals, the judge adds. "Drugs compounded from legal bulk ingredients do not violate the (FD&C) Act's unsafe, adulterated or misbranded provisions."

Related Content:

Regulatory
What you need to know about GFI #256 and the changing landscape of compounding medicine
What you need to know about GFI #256 and the changing landscape of compounding medicine
3 common misconceptions in controlled substance regulations
3 common misconceptions in controlled substance regulations
FDA hosts virtual listening session on regulation of animal food
FDA hosts virtual listening session on regulation of animal food

Advertisement

Latest News

The Vets appoints Dr Zach Mills to VP of Medical Performance

Communicating the importance of genetic screening

Purina announces its 2023 Pet Care Innovation Prize winners

AmeriVet Veterinary Partners deemed a 2022 Business of the Year

View More Latest News
Advertisement